SAN DIEGO, Jan. 10 /PRNewswire-FirstCall/ -- Sequenom, Inc. today announced that through its exclusive South Korean distributor Bioneer Corporation (Kosdaq: 064550) the Company sold three MassARRAY(R) genetic analysis systems in the region during the fourth quarter of 2006 including a sale to the world-class National Cancer Center of the Republic of Korea.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
In September 2006, Bioneer was named as the exclusive distributor and promoter of Sequenom’s genetic analysis products for South Korea. Bioneer also operates a core facility that provides contract services for human, livestock, and agricultural applications throughout South Korea using Sequenom’s MassARRAY system and consumable products. Under its relationship with Sequenom, Bioneer offers MassARRAY-based product and service solutions for fine mapping genotyping, gene and biomarker discovery, validation, screening, DNA methylation marker pattern analysis (epigenetic studies), and quantitative gene expression analysis.
“These sales represent the increased demand we are seeing in South Korea for fine mapping genetic analysis solutions and for life sciences research tools in general,” said Dr. Han-Oh Park, President and Chief Executive Officer of Bioneer. “Sequenom’s products and our service offerings provide compelling value and are especially well suited for fine mapping genotyping, a market that is emerging in South Korea as researchers complete their whole genome studies. Sequenom’s products are similarly attractive for DNA methylation pattern and gene expression analysis projects being conducted by prominent cancer research centers.”
“We look forward to future sales growth in the South Korean market as we continue to build our relationship with Bioneer,” said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom.
About Bioneer Corporation
Bioneer, established in 1992, has developed a broad range of proprietary products that provide total genomic research solutions for life sciences research including genomics, nucleic acid-based molecular diagnostics and gene therapy studies. Bioneer has extensive R&D experience in developing new drugs, use of siRNA and drug delivery systems, and provides unrivalled service and support for such tools. Through the creation, development, and availability of the S.pombe deletion mutant library, Bioneer provides innovative tools for improving the development of new drugs. For example, this library predicts the toxicity of chemical substances for anti-cancer, Hyperlipidemia and also provides molecular level mechanism analysis of natural compound drugs. The company is headquartered in South Korea with an oligonucleotide manufacturing facility in the U.S., regional offices in Europe, and is supported by a network of distributors throughout the world. For more information, please visit www.bioneer.com.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine, agricultural applications, and non-invasive prenatal testing. The Company’s proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding demand in South Korea for fine mapping genetic analysis solutions and life sciences research tools, the emerging fine mapping genotyping market in South Korea, and future sales growth in South Korea, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with acceptance of and demand for Sequenom’s products, reliance upon the collaborative efforts of others such as Bioneer, and other risks detailed from time to time in Sequenom’s SEC filings, including Sequenom’s Annual Report on Form 10-K for the year ended December 31, 2005, and its most recently filed quarterly report on Form 10-Q and subsequent filings. These forward-looking statements are based on current information that is likely to change. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Photo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.
CONTACT: John Sharp, Principal Financial Officer of Sequenom, Inc.,+1-858-202-9032; or Zachary Bryant, zbryant@lhai.com, or Jody Cain,jcain@lhai.com, both of Lippert/Heilshorn & Associates, +1-310-691-7100,for Sequenom, Inc.
